JPMorgan Chase stock today: JPM ends 2025 at $322 as Javice legal-fee fight resurfaces ahead of earnings
1 January 2026
2 mins read

JPMorgan Chase stock today: JPM ends 2025 at $322 as Javice legal-fee fight resurfaces ahead of earnings

NEW YORK, January 1, 2026, 10:26 ET — Market closed

  • JPMorgan shares last closed down 0.37% at $322.22 on Dec. 31.
  • A newly unsealed Delaware filing detailed the bank’s bid to stop paying disputed legal fees tied to Charlie Javice.
  • Next focus is JPMorgan’s Jan. 13 earnings, alongside key U.S. data on jobs and inflation.

JPMorgan Chase & Co shares (JPM.N) last closed down 0.37% at $322.22 on Wednesday, the final session of 2025. U.S. markets are closed on Thursday for the New Year’s Day holiday. 1

A Delaware court filing released this week laid out JPMorgan’s latest effort to avoid disputed legal bills tied to the Charlie Javice case, adding a fresh headline risk as bank earnings season nears. 2

The timing matters because big banks are about to start reporting results, and investors have been re-pricing rate expectations into year-end. Treasury yields moved higher on Wednesday after data showed an unexpected dip in jobless claims, a backdrop that can swing bank valuations quickly. 3

JPMorgan’s dip came with a broader market pullback on Wednesday, with the S&P 500 down 0.74% and the Dow off 0.63%, according to MarketWatch data. Bank of America fell 0.51% and Wells Fargo slipped 1.18% in the same session. 1

In the Delaware filing, JPMorgan described what it called an “unconscionable” $74 million legal-fee tab and said more than $5 million of it related to lawyers and staff attending Javice’s fraud trial, including on days court was not in session. 2

The bank is seeking to avoid $10.2 million in disputed charges and to end any requirement that it pay future bills, the filing said. Javice was convicted in March in connection with a $175 million deal, the report said. 2

Funding markets were also in focus into year-end. The New York Fed’s Standing Repo Facility — a backstop that lends cash against high-quality collateral — saw a record $74.6 billion borrowed on Wednesday, while $106 billion was parked at the Fed’s reverse repo facility, Reuters reported. 4

Scott Skyrm of Curvature Securities said “the funding market is more secure” and there is “more confidence that the SRF is working.” 4

Investors are also tracking the labor market after initial jobless claims fell to 199,000 for the week ended Dec. 27, the lowest since late November, Reuters reported. The Labor Department is scheduled to publish December employment figures on Jan. 9. 5

For banks, the swing factor remains net interest income — the difference between what a lender earns on loans and securities and what it pays depositors and other funding sources. Shifts in long-term yields can help margins, but higher short-term rates can keep deposit costs elevated.

Before the next session on Friday, traders will be watching whether year-end funding pressures fade as liquidity conditions normalize. U.S. stock trading is set to resume on Jan. 2 after Thursday’s holiday closure. 6

The next major catalyst for JPMorgan is its fourth-quarter and full-year 2025 report on Jan. 13, with results due around 7:00 a.m. ET and a conference call at 8:30 a.m. ET, the company said. That morning also brings the U.S. consumer price index for December at 8:30 a.m. ET, a potential driver for rate expectations. 7

Technically, JPM ended Wednesday near the low end of its day’s range ($322.04 to $324.88) after a two-day slide from a Dec. 30 close of $323.42. The $322 area has acted as near-term support, while a move back above the mid-$320s would put the recent trading band back in view. 8

Stock Market Today

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
Robinhood stock today: HOOD slides after December trading snapshot and Goldman target trim
Previous Story

Robinhood stock today: HOOD slides after December trading snapshot and Goldman target trim

Eli Lilly stock ends 2025 lower as 2026 drug-price shifts and GLP-1 pill race come into focus
Next Story

Eli Lilly stock ends 2025 lower as 2026 drug-price shifts and GLP-1 pill race come into focus

Go toTop